Laboratory diagnosis and monitoring of diabetes mellitus

American Journal of Clinical Pathology

Volumn 112, Issue 5, 1999, Pages 665-674

  Emancipator, Kenneth ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Glucose tolerance testing; Hyperglycemia; Plasma glucose levels

Indexed keywords

1,5 ANHYDROSORBITOL; ALBUMIN; C PEPTIDE; CATECHOLAMINE; CREATININE; FRUCTOSAMINE; GLUCAGON; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; KETONE;

ARTICLE; CREATININE URINE LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIAGNOSTIC VALUE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HORMONE DETERMINATION; IMPAIRED GLUCOSE TOLERANCE; MICROALBUMINURIA; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; SELF MONITORING; SEROLOGY;

EID: 0033491394     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/112.5.665     Document Type: Article

References (55)

1. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
2. ADA meeting news: new guidelines for diagnosing diabetes [press release]. Alexandria, VA: American Diabetes Association; June 23, 1997.
3. Emancipator K. Laboratory diagnosis and monitoring of diabetes mellitus. Clinical Chemistry Check Sample CC 98-5. Chicago, IL: ASCP; 1998.
4. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
5. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 1997.
6. O'Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. Diabetes. 1964;13:278-285.
7. American Diabetes Association. Gestational diabetes mellitus [position statement]. Diabetes Care. 1991;14(suppl 2):5-6.
8. Coustan DR. Screening and diagnosis of gestational diabetes. Semin Perinatol. 1994;18:407-413.
9. McFarland K. The role of glycated hemoglobin in pregnancy. In: The Role of Glycated Hemoglobin in the Management of Diabetes [Proceedings of September 16, 1988 symposium]. Akron, OH: Isolab.
10. Kjos SL, Buchanan TA, Greenspoon JS, et al. Gestational diabetes mellitus: the prevalence of glucose intolerance and diabetes mellitus in the first two months postpartum. Am J Obstet Gynecol. 1990;163:93-98.
11. Dacus JV, Meyer NL, Muram D, et al. Gestational diabetes: postpartum glucose tolerance testing. Am J Obstet Gynecol. 1994;171:927-931.
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
13. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
14. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control policy with metformin on complications in type 2 diabetes patients (UKPDS 34). Lancet. 1998;352:854-865.
15. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care. 1995;18:896-909.
16. Foster DW. Diabetes mellitus. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill; 1994:1979-2000.
17. Sacks DB. Carbohydrates. In: Burtis CA, Ashwood ER, eds. Tietz' Textbook of Clinical Chemistry. Philadelphia, PA: Saunders; 1994:928-1001.
18. Porter WH, Yao HH, Karounos DG. Laboratory and clinical evaluation of assays for beta-hydroxybutyrate. Am J Clin Pathol. 1997;107:353-358.
19. Teupe B. Quantitative determination of glycated hemoglobin using affinity chromatography. In: The Role of Glycated Hemoglobin in the Management of Diabetes [Proceedings of September 16, 1988 symposium]. Akron, OH: Isolab.
20. American Diabetes Association. Tests of glycemia in diabetes [position statement]. Diabetes Care. 1998;21(suppl 1):S69-S71.
21. 1 in diabetic patients. Clin Biochem. 1981;14:25-27.
22. Bodor GS, Little RR, Garrett N, et al. Standardization of glycohemoglobin determinations in the clinical laboratory: three years experience. Clin Chem. 1992;38:2414-2418.
23. Little RR, Wiedmeyer HM, England JD, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem. 1992;38:2472-2478.
24. 1c. Clin Chem. 1992;38:2372-2379.
25. Nathan DM, Avezzano ES, Palmer JL. A rapid chemical means for removing labile glycohemoglobin. Diabetes. 1981;30:700-701.
26. Schapfel D, Bock JL. Glycohemoglobin. Clinical Chemistry Check Sample CC 97-5. Chicago, IL: ASCP; 1997.
27. Koch DD. Fructosamine: how useful is it? Lab Med. 1990;21:497-503.
28. Benjamin RJ, Sacks DB. Glycated protein update: implications of recent studies, including the Diabetes Control and Complications Trial. Clin Chem. 1994;40:683-687.
29. Lin MJ, Hoke C, Ettinger B, et al. Technical performance evaluation of BM/Hitachi 747-200 serum fructosamine assay. Clin Chem. 1996;42:244-248.
30. Eder AF. Laboratory tests for glycemic control in diabetes. Clinical Chemistry Check Sample CC 97-8. Chicago, IL: ASCP; 1997.
31. Cohen MP, Hud E. Production and characterization of monoclonal antibodies against human glycoalbumin. J Immunol Methods. 1989;117:121-129.
32. Hud E, Cohen MP. Evaluation and performance characteristics of a novel ELISA using monoclonal antibody to glycated albumin. Clin Chim Acta. 1989;185:157-164.
33. Ikeda K, Sakamoto Y, Kawasaki Y, et al. Determination of glycated albumin by enzyme-linked boronate immunoassay (ELBIA). Clin Chem. 1998;44:256-263.
34. Yamanouchi T, Ogata N, Tagaya T, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet. 1996;347:1514-1518.
35. Frattali AL, Wolf BA. 1,5-anhydroglucitol: a novel serum marker for screening and monitoring diabetes mellitus? [editorial]. Clin Chem. 1994;40:1991-1993.
36. Peters AL, Davidson MB, Schriger DL, et al. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. JAMA. 1996;276:1246-1252.
37. 1c and fructosamine levels in diagnosis of gestational diabetes mellitus. Clin Exp Obstet Gynecol. 1995;22:230-234.
38. Cefalu WT, Prather KL, Chester DL, et al. Total serum glycosylated proteins in detection and monitoring of gestational diabetes. Diabetes Care. 1990;13:872-875.
39. Saleraans TH, van Dieijen-Visser MP, Brombacher PJ, et al. Value of maternal fructosamine in the screening of an unselected population for hyperglycemia-related complications in the newborn. Am J Perinatol. 1994;11:4-8.
40. Hughes PF, Agarwal M, Newman P, et al. An evaluation of fructosamine estimation in screening for gestational diabetes mellitus. Diabetes Med. 1995;12:708-712.
41. American Diabetes Association. Diabetic nephropathy [position statement]. Diabetes Care. 1998;21(suppl 1):S50-S53.
42. Silverman LM, Christenson RH. Amino acids and proteins. In: Burtis CA, Ashwood ER, eds. Tietz' Textbook of Clinical Chemistry. Philadelphia, PA: Saunders; 1994:625-734.
43. Bennett PH, Haffher S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis. 1995;25:107-112.
44. Zelmanovitz T, Gross JL, Oliveira JR, et al. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care. 1997;20:516-519.
45. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317:703-713.
46. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J. 1998;317:713-720.
47. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. Br Med J. 1998;317:720-726.
48. Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. Br Med J. 1998;317:693-694.
49. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080-1084.
50. Magnotti RA, Ghosn SJ. Microalbuminuria. Clinical Chemistry Check Sample CC 95-3. Chicago, IL: ASCP; 1995.
51. Tomaselli L, Trischitta V, Vinci C, et al. Evaluation of albumin excretion rate in overnight versus 24-h urine. Diabetes Care. 1989;12:585-587.
52. Cundy TF, Nixon D, Berkahn L, et al. Measuring the albumin excretion rate: agreement between methods and biological variability. Diabetes Med. 1992;9:138-143.
53. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21:160-178.
54. American Diabetes Association. Management of dyslipidemia in adults with diabetes [position statement]. Diabetes Care. 1998;21:S36-S39.
55. Christie MR, Hatfiels CCI, Roll U, et al. Validity of screening for individuals at risk for type 1 diabetes by combined analysis of antibodies to recombinant proteins. Diabetes Care. 1997;20:965-970.